Dr Eric Mayes

Dr Eric Mayes

Endomag

Eric-Mayes-headshot1-CSP-PROFILEBreast cancer affects 1.7 million people worldwide, and from 2016-2020 the number afflicted is expected to increase by 30 per cent.

Seeking to reduce the barriers that obstruct those in need from the best standard of care in surgical oncology is Endomag, a developer of new techniques for the diagnosis and treatment of cancer.

A Fellow of the Royal Society of Chemistry and an experienced player in early stage ventures, CEO Eric Mayes is playing to his strengths and helping lead the firm’s research as well as commercial efforts.

Eric says that the team at Endomag are constantly achieving innovation because they have the freedom to combine existing technologies in novel ways. It’s working, and it’s saving lives. To date, Endomag products have treated more than 12,500 breast cancer patients.

For Eric, there is a burgeoning role for business in wider society, “The provision of essential resources to society, such as water, food, energy and healthcare, is typically the domain of the public sector.”

If business decided to take more of an interest in these needs, then everyone could benefit, he adds: “Clearly it could be good business to focus on the greatest needs of society, as the impact can be much more significant – both for the business and for society.”

Further reading

Meet other faces